Clinical Trial Update: Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

View source ↗

Summary

Adalimumab has received marketing approval for active rheumatoid arthritis under an early access program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Rheumatoid Arthritis | Status: APPROVED_FOR_MARKETING